DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

Oppenheimer Upgrades Homology Medicines to Outperform, Announces $32 Price Target

Oppenheimer analyst Matthew Biegler upgrades Homology Medicines (NASDAQ:FIXX) from Perform to Outperform and announces $32 price target.

Benzinga · 03/16/2020 09:56

Oppenheimer analyst Matthew Biegler upgrades Homology Medicines (NASDAQ:FIXX) from Perform to Outperform and announces $32 price target.